Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp (KTTAW) is a clinical-stage biotechnology company pioneering treatments for central nervous system disorders and RASopathies. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access verified news about the company’s pipeline progress, including its lead candidate PAS-004 (a macrocyclic MEK inhibitor), trial design updates, and collaborations. Our curated collection features press releases on:
• Clinical trial phases
• Research partnerships
• Regulatory submissions
• Scientific publications
Bookmark this page for centralized access to Pasithea’s latest advancements in neurofibromatosis, ALS, and schizophrenia research. Check regularly for objective updates on therapeutic innovations and corporate developments shaping the biotechnology landscape.
FAQ
What is the current stock price of Pasithea Therapeutics (KTTAW)?
